Navigation Links
Elcelyx Therapeutics Reports Positive Data for NewMet in Type 2 Diabetes at 2013 American Diabetes Association Scientific Sessions
Date:6/22/2013

es a model designed to predict concentrations of metformin in the blood that would occur if patients with Type 2 diabetes and mild, moderate or severe renal impairment were to take NewMet. The results of the model suggest that patients with renal impairment taking effective doses of NewMet would not have an increased risk of lactic acidosis caused by accumulation of metformin in the blood. Elcelyx will be initiating a pharmacokinetic study this summer in Type 2 diabetes patients with mild, moderate and severe renal impairment to confirm the predictions of the model.

"Metformin is the preferred initial pharmacological agent for Type 2 diabetes, but in the U.S., 40% of patients with diabetes are not taking it primarily due to issues of GI tolerability or due to the contraindication of their renal impairment. Moreover, of the 60% who are taking metformin, only about 40% are able to titrate to fully effective doses due to tolerability issues," said John Buse, M.D., Professor of Medicine and Director, Diabetes Care Center, Chief, Division of Endocrinology, Executive Associate Dean for Clinical Research at University of North Carolina School of Medicine, Chapel Hill, North Carolina. "The NewMet results to date hold the promise of addressing all these patient segments. This is very encouraging news for physicians who would like to be in compliance with ADA treatment guidelines and have their patients benefit from metformin therapy." Dr. Buse was an advisor on the Phase 2a NewMet clinical study.

To confirm results observed to date, a multicenter, double-blind dose-finding Phase 2b trial evaluating NewMet once-daily doses of 1,000, 800 and 600 milligrams compared to placebo is underway.  There are also two comparator arms with generic extended-release metformin dosed once-daily at 1,000 and 2,000 milligrams. The primary endpoint of the study is fasting plasma glucose at four weeks of treatment. Seconda
'/>"/>

SOURCE Elcelyx Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
2. Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
3. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
4. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
6. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
(Date:7/10/2014)... NEWPORT NEWS, Virginia , 11. ... führender Hersteller von Kameras für die ... Brust (MBI/BSGI), hat heute die CE-Zulassung ... Mit dem CE-Zeichen kann Dilon das ... seinen Vertriebsbereich auf den Großteil der ...
(Date:7/10/2014)... U.S. Department of Health and Human Services (HHS) has ... Medical Center Seidman Cancer Center totaling $4.7 million to ... for patients with complex cancer. Titled ... model developed at UH to enhance care for adult ... need for high health care utilization.  ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... 2011 Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ... granted orphan drug designation for tasimelteon, an oral dual ... Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals with no ... designation that the Committee for Orphan Medicinal Products (COMP) ...
... China, March 8, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ... a leading pharmaceutical company specializing in the development, manufacturing, ... today reported unaudited financial results for the fourth quarter ... Highlights Total revenue was ...
Cached Medicine Technology:Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 2Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 3Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon 4Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 2Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 3Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 4Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 5Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 6Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 7Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 8Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 9Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 10Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 11Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results 12
(Date:7/11/2014)... This morning(July 9th, 2014 at 8 am), ... discuss the illegal immigration crisis at our southern border and ... , Dr. Flinn told Good Morning Memphis host Ernie Freeman, ... The problem is that they do not have enough agents ... day are coming into the border; the border isn’t protected.” ...
(Date:7/11/2014)... 11, 2014 People with physical disabilities ... some of the increasing numbers of people partnered with ... independent and productive lives. , But are these ... an assistance dog an impediment to employment? , ... August 3 - 9, 2014, West Virginia University associate ...
(Date:7/11/2014)... July 11, 2014 The Williams Rejuva ... part of each patient’s unique treatment regime. Using ... skin’s health and trouble areas can be quickly created. ... to be established. , Vectra 3D is a cutting-edge ... Vectra 3D uses a quick ‘snapshot’ of the skin ...
(Date:7/11/2014)... Texas (PRWEB) July 11, 2014 Yisrayl Hawkins, ... Texas, writes a letter pleading to let the children from ... to be allowed to come. Yisrayl says President Barack Obama ... need from the United States, and he wants to help ... children coming from Guatemala, Honduras and El Salvador being treated ...
(Date:7/11/2014)... Even the hot Texas sun won’t keep kids from having ... The school had previously invested in a playground structure to ... recently asked for an innovative solution to help protect children ... chose a Rectangular Shade from APCPLAY as the perfect solution ... The shade measures 24’W x 34’H x 11’H to ...
Breaking Medicine News(10 mins):Health News:Senate Candidate, George Flinn on Fox13 NEWS About the Border Crisis 2Health News:Will Your Next Employee or Co-Worker Be a Dog? 2Health News:Will Your Next Employee or Co-Worker Be a Dog? 3Health News:Will Your Next Employee or Co-Worker Be a Dog? 4Health News:Williams Rejuva Center Includes Innovative Computer Imaging 2Health News:Yisrayl Hawkins Backs Barack Obama’s Pleas to Let the Children Come to the U.S. in New Letter 2Health News:Yisrayl Hawkins Backs Barack Obama’s Pleas to Let the Children Come to the U.S. in New Letter 3Health News:Cool Fun Under the Texas Sun: Godley Elementary School Purchases Shade Structure from APCPLAY© 2
... working to ... Oct. 15 More than half of the children in,Indianapolis ... University School of Dentistry mobile project had moderate or,severe dental ... by the,university and funded in part by a grant from ...
... mathematician who has applied mathematical modeling techniques to elucidate the ... methods to ascertain the players most deserving of major league ... awards. Bukiet, a popular NJIT math professor, dives annually ... game, but also for his love of teaching and math. ...
... DUBLIN, Ohio, Oct. 15 Foresight Corporation ... Debra Strickland has joined the,company,s Development division ... http://www.newscom.com/cgi-bin/prnh/20081015/CLW134 ), In this role, ... customers to,propose and design new technical solutions, ...
... 15 deCODE genetics,(Nasdaq: DCGN ) today ... review of,its long-term business strategy. Over the past ... chemistry, structural biology and,human genetics to develop product ... diagnostics. The goal of this strategic,review is to ...
... Thanks Donor Family for New Hand, LOUISVILLE, Ky., ... transplant recipient headed home,yesterday (Oct. 14) to Upland, California, ... new right hand during a 14-hour surgical,procedure performed by ... on July 12, 2008 at Jewish Hospital., "I ...
... Cenegenics Education and Research Foundation partnered with two recognized ... of Medicine to examine testosterone and/or human growth hormone ... body composition and quality of life. Favorable findings from ... Journal of Multidisciplinary Healthcare, part of Dove Open Access. ...
Cached Medicine News:Health News:SEAL Indiana Reports More Than Half of Indianapolis Area School Kids Treated by Program Have Moderate or Severe Dental Decay 2Health News:Using math model, NJIT professor names MVP and Cy Young award contenders 2Health News:Using math model, NJIT professor names MVP and Cy Young award contenders 3Health News:Debra Strickland joins Foresight Corporation in time for HIPAA 5010 Mandate 2Health News:deCODE Conducting Strategic Review to Sharpen the Focus of its Long-term Business 2Health News:deCODE Conducting Strategic Review to Sharpen the Focus of its Long-term Business 3Health News:deCODE Conducting Strategic Review to Sharpen the Focus of its Long-term Business 4Health News:Fourth Hand Transplant Recipient Heads Home to California 2Health News:Hormone Normalization Shows Encouraging Effects In Documented Clinically Deficient Men/Women 2Health News:Hormone Normalization Shows Encouraging Effects In Documented Clinically Deficient Men/Women 3
... when it comes to superior immobilization and cervical ... job., ,You already know that the most ... of the c-spine. But what you may not ... Medical's NECLOC ®: provides superior immobilization over the ...
Distinct male and female designs for proper anatomical fit. Hip and pelvic components sized independently. Rigid posterior tongue minimizes pelvic rotation. Available in black or white plastic. Aggre...
... The B3 Triplanar hip joint ... Flexion - extension, abduction - ... on our Boston Post-Op Hip ... our custom Hip Spicas in ...
... Impact is the most significant advance in walker design ... unique design where the weight bearing surfaces of the ... impact is absorbed at the heel strike. The footbed ... the foot for added comfort and stability. , ...
Medicine Products: